Vaxxinova is Granted Regulatory Approval for Vaxxon® Yersinia vet

Bergen, Norway, June 25, 2026 – Vaxxinova is pleased to announce that Vaxxon Yersinia vet has been granted regulatory approval in Norway by the Norwegian Medical Products Agency  (NOMA).

Vaxxon Yersinia vet is an inactivated vaccine developed for Atlantic salmon targeting Yersinia ruckeri, the causative agent of Enteric Redmouth Disease (ERM) in salmonids, a bacterial infection affecting farmed fish.
This approval marks an important milestone as Vaxxinova’s first registered vaccine for salmon and reflects strong collaboration across teams throughout the development and regulatory process.
“Receiving regulatory approval from NOMA is a significant achievement for us and an important step in bringing our vaccine portfolio to the salmon industry,” says Matias del Campo, Managing director of Vaxxinova Norway and Chile.